Baidu
map

JAMA Oncol:22基因基因组分类器可预测前列腺癌术后远处转移风险!

2021-02-13 Nebula MedSci原创

Decpher(Decpher Biosciences Inc)是一种基因组分类器(GC),用于评估前列腺癌患者前列腺癌根治术(RP)后发生远处转移(DM)的风险。

Decpher(Decpher Biosciences Inc)是一种基因组分类器(GC),用于评估前列腺癌患者前列腺癌根治术(RP)后发生远处转移(DM)的风险。

本研究对1998年3月-2003年3月期间开展的以安慰剂为对照的III期NRG/RTOG 9601随机临床试验的RP切除样本进行的辅助性研究,旨在在随机3期试验的背景下验证GC。研究人员对样本进行了集中审查,并从2019年可用的高级别肿瘤中提取了RNA,通过质量控制后给予GC评分(0-1分)。预定的主要终点是GC与DM发展的独立关联。

在该研究中,对760位随机试验患者中的486位进行了GC评分,中位随访了13年;来自352位男性(中位年龄 64.5岁;314位白种人[89.2%]的样本,通过了微阵列质量控制,组成了用于分析的最终队列。

在多变量分析中,经年龄、种族/民族、格里森评分、T分期、切缘状态、前列腺特异性抗原和治疗校准后,GC与DM(风险比 1.17;95%CI 1.05-1.32;P=0.006)、PCSM(1.39;1.2 0-1.63;P<0.001)、OS(1.17;1.06~1.29;P=0.002)独立相关。虽然原计划的分析不能通过GC评分来检测治疗效果的相互作用,但将GC评分较低和较高的患者相比时,比卡鲁胺(bicalutamide)对12年OS的估计绝对效果较小(2.4% vs 8.9%),该结果在接受前列腺特异性抗原水平低于0.7 ng/mL时接受早期sRT的男性中进一步得到了证实(-7.8% vs 4.6%)。

总之,本研究表明,GC与DM、PCSM和OS之间存在独立于标准临床病理变量之外的相关性。这些结果表明,并不是所有术后生化复发的前列腺癌患者都能从以sRT为基础的治疗加用激素治疗中获益。

原始出处:

Feng Felix Y,Huang Huei-Chung,Spratt Daniel E et al. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol, 2021, 10.1001/jamaoncol.2020.7671.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1813712, encodeId=43d51813e12ce, content=<a href='/topic/show?id=f6319345919' target=_blank style='color:#2F92EE;'>#转移风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93459, encryptionId=f6319345919, topicName=转移风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Dec 22 08:33:09 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866009, encodeId=1f4d186600900, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Feb 14 05:33:09 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423499, encodeId=2950142349943, content=<a href='/topic/show?id=badd9441868' target=_blank style='color:#2F92EE;'>#远处转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94418, encryptionId=badd9441868, topicName=远处转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c42b3793913, createdName=hanhaisha2009, createdTime=Mon Feb 15 06:33:09 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036451, encodeId=6ec210364519b, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038211, encodeId=12fe103821158, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040957, encodeId=7de1104095e27, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924460, encodeId=afcb92446013, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Feb 13 15:36:59 CST 2021, time=2021-02-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1813712, encodeId=43d51813e12ce, content=<a href='/topic/show?id=f6319345919' target=_blank style='color:#2F92EE;'>#转移风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93459, encryptionId=f6319345919, topicName=转移风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Dec 22 08:33:09 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866009, encodeId=1f4d186600900, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Feb 14 05:33:09 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423499, encodeId=2950142349943, content=<a href='/topic/show?id=badd9441868' target=_blank style='color:#2F92EE;'>#远处转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94418, encryptionId=badd9441868, topicName=远处转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c42b3793913, createdName=hanhaisha2009, createdTime=Mon Feb 15 06:33:09 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036451, encodeId=6ec210364519b, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038211, encodeId=12fe103821158, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040957, encodeId=7de1104095e27, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924460, encodeId=afcb92446013, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Feb 13 15:36:59 CST 2021, time=2021-02-13, status=1, ipAttribution=)]
    2021-02-14 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1813712, encodeId=43d51813e12ce, content=<a href='/topic/show?id=f6319345919' target=_blank style='color:#2F92EE;'>#转移风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93459, encryptionId=f6319345919, topicName=转移风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Dec 22 08:33:09 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866009, encodeId=1f4d186600900, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Feb 14 05:33:09 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423499, encodeId=2950142349943, content=<a href='/topic/show?id=badd9441868' target=_blank style='color:#2F92EE;'>#远处转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94418, encryptionId=badd9441868, topicName=远处转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c42b3793913, createdName=hanhaisha2009, createdTime=Mon Feb 15 06:33:09 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036451, encodeId=6ec210364519b, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038211, encodeId=12fe103821158, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040957, encodeId=7de1104095e27, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924460, encodeId=afcb92446013, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Feb 13 15:36:59 CST 2021, time=2021-02-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1813712, encodeId=43d51813e12ce, content=<a href='/topic/show?id=f6319345919' target=_blank style='color:#2F92EE;'>#转移风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93459, encryptionId=f6319345919, topicName=转移风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Dec 22 08:33:09 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866009, encodeId=1f4d186600900, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Feb 14 05:33:09 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423499, encodeId=2950142349943, content=<a href='/topic/show?id=badd9441868' target=_blank style='color:#2F92EE;'>#远处转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94418, encryptionId=badd9441868, topicName=远处转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c42b3793913, createdName=hanhaisha2009, createdTime=Mon Feb 15 06:33:09 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036451, encodeId=6ec210364519b, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038211, encodeId=12fe103821158, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040957, encodeId=7de1104095e27, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924460, encodeId=afcb92446013, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Feb 13 15:36:59 CST 2021, time=2021-02-13, status=1, ipAttribution=)]
    2021-02-13 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1813712, encodeId=43d51813e12ce, content=<a href='/topic/show?id=f6319345919' target=_blank style='color:#2F92EE;'>#转移风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93459, encryptionId=f6319345919, topicName=转移风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Dec 22 08:33:09 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866009, encodeId=1f4d186600900, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Feb 14 05:33:09 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423499, encodeId=2950142349943, content=<a href='/topic/show?id=badd9441868' target=_blank style='color:#2F92EE;'>#远处转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94418, encryptionId=badd9441868, topicName=远处转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c42b3793913, createdName=hanhaisha2009, createdTime=Mon Feb 15 06:33:09 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036451, encodeId=6ec210364519b, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038211, encodeId=12fe103821158, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040957, encodeId=7de1104095e27, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924460, encodeId=afcb92446013, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Feb 13 15:36:59 CST 2021, time=2021-02-13, status=1, ipAttribution=)]
    2021-02-13 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1813712, encodeId=43d51813e12ce, content=<a href='/topic/show?id=f6319345919' target=_blank style='color:#2F92EE;'>#转移风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93459, encryptionId=f6319345919, topicName=转移风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Dec 22 08:33:09 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866009, encodeId=1f4d186600900, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Feb 14 05:33:09 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423499, encodeId=2950142349943, content=<a href='/topic/show?id=badd9441868' target=_blank style='color:#2F92EE;'>#远处转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94418, encryptionId=badd9441868, topicName=远处转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c42b3793913, createdName=hanhaisha2009, createdTime=Mon Feb 15 06:33:09 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036451, encodeId=6ec210364519b, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038211, encodeId=12fe103821158, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040957, encodeId=7de1104095e27, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924460, encodeId=afcb92446013, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Feb 13 15:36:59 CST 2021, time=2021-02-13, status=1, ipAttribution=)]
    2021-02-13 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1813712, encodeId=43d51813e12ce, content=<a href='/topic/show?id=f6319345919' target=_blank style='color:#2F92EE;'>#转移风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93459, encryptionId=f6319345919, topicName=转移风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Dec 22 08:33:09 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866009, encodeId=1f4d186600900, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Feb 14 05:33:09 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423499, encodeId=2950142349943, content=<a href='/topic/show?id=badd9441868' target=_blank style='color:#2F92EE;'>#远处转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94418, encryptionId=badd9441868, topicName=远处转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c42b3793913, createdName=hanhaisha2009, createdTime=Mon Feb 15 06:33:09 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036451, encodeId=6ec210364519b, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038211, encodeId=12fe103821158, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040957, encodeId=7de1104095e27, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 13 18:33:09 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924460, encodeId=afcb92446013, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Feb 13 15:36:59 CST 2021, time=2021-02-13, status=1, ipAttribution=)]
    2021-02-13 jyzxjiangqin

    好文章!

    0

相关资讯

Cell Death Dis:前列腺癌微环境中雄激素受体/丝胺A复合物的靶向作用

前列腺癌是男性癌症相关死亡的主要原因,患者经常出现耐药性和转移性疾病。大多数研究集中在与雄激素受体突变有关或与前列腺癌细胞过度激活信号通路的获得特性有关的激素耐药机制。肿瘤微环境在前列腺癌的进展中起着

Commun Biol:循环细胞外小体释放致癌性miR-424

细胞外小体(EVs)是细胞间信号转移的相关手段,能够促进致癌刺激的传播以及癌症患者的疾病演变和转移的扩散。

JAMA Netw Open:恩扎鲁胺与比卡鲁胺联合雄激素阻断疗法对转移激素敏感型前列腺癌男性的临床疗效

最近,有研究人员比较了恩杂鲁胺与比卡鲁胺联合使用ADT对男性mHSPC的疗效,并对黑人患者进行了亚组分析。

Prostate Cancer P D:健康和前列腺癌不同阶段男性的身体成分、身体功能和生活质量

最近,有研究人员比较了PC和非癌症对照组(CON)各进展阶段组患者的身体成分、身体功能和QoL情况。

Clin Cancer Res:醋酸阿比特龙通过诱导CREB1磷酸化和增强CBP-p300复合物的功能导致前列腺癌细胞产生耐药

醋酸阿比特龙(AA)是CYP17A1的抑制剂,是FDA批准的治疗晚期前列腺癌的药物。然而,并非所有患者都对AA有响应,最初有反应的患者最终也会产生AA耐药性。最近,有研究人员确定了前列腺癌细胞的AA耐

Clin Cancer Res:基线循环肿瘤细胞计数可作为转移去势敏感前列腺癌PSA响应和疾病进展的预后标志

在转移性去势敏感性前列腺癌(mCSPC)中,联合雄激素抑制是一种标准治疗。但需要指导初始治疗决策的非侵入性生物标志物。最近,有研究人员假设CellSearch CTC计数是转移去势抗性PC(mCRPC

Baidu
map
Baidu
map
Baidu
map